Automate Your Wheel Strategy on HROW
With Tiblio's Option Bot, you can configure your own wheel strategy including HROW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HROW
- Rev/Share 5.9414
- Book/Share 1.5658
- PB 20.0041
- Debt/Equity 4.0744
- CurrentRatio 0.9067
- ROIC 0.0159
- MktCap 1156771392.0
- FreeCF/Share -1.0218
- PFCF -31.5989
- PE -52.0488
- Debt/Assets 0.6316
- DivYield 0
- ROE -0.3577
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HROW | BTIG Research | -- | Buy | -- | $62 | June 12, 2025 |
| Initiation | HROW | William Blair | -- | Outperform | -- | -- | June 10, 2025 |
| Initiation | HROW | H.C. Wainwright | -- | Buy | -- | $57 | Feb. 6, 2025 |
| Reiterated | HROW | B. Riley Securities | -- | Buy | $73 | $69 | Dec. 4, 2024 |
News
Harrow: Epic Growth & Operating Leverage On Full Display
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Positive
Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Management is guiding for this to not only continue, but actually accelerate. Harrow's operating leverage is plainly evident in the data. EBITDA margins have risen sharply as the company has grown, and management has guided for this to accelerate in 2025.
Read More
What Recession? I'm Swimming In Dividends
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
What Recession? I'm Swimming In Dividends
Read More
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral
BERWYN, Pa. , April 24, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V.
Read More
Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H.
Read More
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE. Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All program.
Read More
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
Published: March 27, 2025 by: Business Wire
Sentiment: Neutral
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Fri.
Read More
I Am Loading Up Big Dividends For My Golden Years
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.
Read More
About Harrow Health, Inc. (HROW)
- IPO Date 2007-09-28
- Website https://www.harrowinc.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Mark L. Baum J.D.
- Employees 382